慢性便秘 中国就医指南

Chronic constipation is a common functional gastrointestinal disorder characterized by persistent difficulty in passing stools, infrequent bowel movements (typically fewer than three per week), and/or a sensation of incomplete evacuation, straining, or rectal blockage—lasting for at least six months, with symptoms present for the last three months. It is not attributable to structural, metabolic, or systemic disease, nor solely explained by medication use or inadequate fiber intake. Pathophysiologically, chronic constipation arises from complex interactions among colonic motility dysfunction (e.g., slow-transit constipation), pelvic floor dyssynergia (impaired coordination of abdominal and pelvic floor muscles during defecation), visceral hypersensitivity, altered gut microbiota composition, and dysregulation of the brain-gut axis. Neurotransmitter imbalances—including reduced serotonin (5-HT) signaling and abnormal enteric nervous system activity—also contribute significantly. Epidemiologically, chronic constipation affects approximately 12–19% of the global adult population, with higher prevalence in women (up to 2.5× more common than in men), older adults (>60 years), and individuals with sedentary lifestyles. In China, community-based studies estimate prevalence at 6–15%, rising sharply with age and urbanization. Key modifiable risk factors include low dietary fiber intake (<20 g/day), chronic dehydration, physical inactivity, excessive use of laxatives (especially stimulant types), opioid or anticholinergic medications, and psychological stressors such as anxiety and depression. Non-modifiable risks include female sex, advancing age, and comorbid conditions like irritable bowel syndrome (IBS-C), diabetes mellitus, hypothyroidism, and Parkinson’s disease. Beyond physiological discomfort, chronic constipation profoundly impairs quality of life: patients report increased fatigue, abdominal bloating and pain, reduced work productivity, social withdrawal, sleep disturbances, and heightened risk of anxiety and depressive disorders. Complications may include hemorrhoids, anal fissures, fecal impaction, and overflow incontinence—particularly in frail elderly populations. Early diagnosis requires careful clinical evaluation, including Rome IV criteria assessment, exclusion of secondary causes (e.g., colonoscopy for red-flag symptoms), and, when indicated, anorectal manometry or colonic transit studies. Patient education on lifestyle modification—fiber optimization (25–35 g/day), timed toilet habits, adequate hydration (1.5–2 L/day), and daily physical activity—is foundational. Multidisciplinary management involving gastroenterologists, dietitians, and pelvic floor physiotherapists improves long-term outcomes and reduces relapse.

# 慢性便秘治疗方案与费用明细（消化内科）

一、非手术/保守治疗方案

适用人群：功能性便秘、轻中度结肠传输延迟或出口梗阻型初诊患者

• •生活方式干预（含膳食指导+排便训练）：0元（门诊随访）
• •基础检查：结肠传输试验（放射性标记法）、肛门直肠测压、球囊排出试验：800–1,500元
• •药物治疗（按疗程3个月计）：

　• 刺激性泻剂（比沙可啶）：60–120元 　• 新型促分泌药（普芦卡必利）：2,880–4,320元（医保乙类，自付约40%）

二、微创/介入治疗方案

适用人群：难治性出口梗阻型便秘、生物反馈治疗无效者

• •经肛门肉毒毒素注射（括约肌松解）：3,200–4,800元（含术前盆底MRI 1,200元）
• •骶神经调控（SNS）一期测试电极植入：45,000–62,000元（含术前神经电生理评估1,800元）

三、手术治疗方案

适用人群：结肠慢传输型且全结肠测压证实重度动力障碍、排除继发性病因者

• •腹腔镜全结肠切除+回直肠吻合术：88,000–126,000元（含术前胃肠道准备、结肠镜+病理、术后营养支持）

四、特殊复杂方案

顽固性合并盆底失弛缓/严重抑郁/糖尿病胃肠病变者：多学科联合管理（消化科+心理科+康复科），年综合费用15,000–35,000元

方案快速选择指南

• •预算＜2,000元/年：首选生活方式干预+聚乙二醇；
• •预算5,000–20,000元：加用普芦卡必利+生物反馈治疗；
• •耐药/严重影响生活质量：优先评估骶神经调控；
• •确诊慢传输型且病程＞5年：转外科评估全结肠切除适应证。